Compare Becton Dickinson and Co (BDX) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Oracle Corporation — how do they compare? Becton Dickinson and Co trades at $154.38 (market cap $41.51B), while Oracle Corporation trades at $133.01 (market cap $368.53B). The key difference: Oracle Corporation is far larger — about 8.9× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | ORCL | |
|---|---|---|
Market Cap | $41.51B | $368.53B |
Sector | Health | Technology |
52-Week High | $185.39 | $328.33 |
52-Week Low | $135.49 | $127.96 |
Enterprise Value | $57.97B | $497.78B |
Dividend Yield | 2.79% | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Oracle (ORCL) trades at $131.86, down 6.27% in the last 24 hours, amid a bearish technical signal but strong fundamental performance. The company reported revenue of $57.40B in 2025 with a net income margin of 25.37%, and has beaten earnings estimates for the last three quarters. Recent news highlights Oracle's AI infrastructure growth and a pending Q2 2026 earnings report on June 10, 2026.
The outlook for Oracle is positive due to robust earnings growth and AI-driven opportunities, though risks include high debt levels and competitive pressures. Analysts maintain a bullish consensus with a $259 price target, suggesting significant upside from the current price if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
